For adults with moderate to severe hidradenitis suppurativa
THE SAFETY OF COSENTYX® (secukinumab) IS WELL STUDIED — WITH 18 YEARS OF CLINICAL TESTING†
Why is an HS treatment with proven experience important?
WORKS WITHIN
COSENTYX® is designed to work within your immune system to regulate one source of HS inflammation.
5.2+ MILLION PRESCRIPTIONS FILLED
Before the FDA approved COSENTYX to treat adults with moderate to severe HS, over 5.2 million COSENTYX prescriptions had been filled‡ in the United States across all indications combined.
COSENTYX has had a well-studied safety profile since its launch in 2015 and has been FDA approved to treat numerous conditions:
2015 — adults with moderate to severe plaque psoriasis
2016 — adults with active ankylosing spondylitis and active psoriatic arthritis
2020 — adults with active non-radiographic axial spondyloarthritis
2021 — children with plaque psoriasis (6 years and older), psoriatic arthritis (2 years and older), and enthesitis-related arthritis (4 years and older)
2023 — adults with moderate to severe hidradenitis suppurativa
†Across all indications combined.
‡As of December 2024.
Individual results may vary. Frank was compensated for his time.
“It took 10 years for me to find out what the bumps under my chest were. When I was finally diagnosed with HS, I found out they were abscesses. I felt relieved and seen. My dermatologist told me about COSENTYX® and I was ready, honey!”
– Frank, actual patient
